FIELD: biotechnology.
SUBSTANCE: invention relates to a new GLP-1/glucagon receptor agonist, and can be used in medicine. Said agonist of the present invention is represented by a derivative of glucagon including a number of amino acid substitutions and in the structure of which an additional lipophilic group and at least 3 negatively charged groups are introduced.
EFFECT: in comparison with the known analogues, the glucagon derivative of the present invention has an increased stability and an increased half-washout period from the body.
16 cl, 80 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| SELECTIVE COMPOUNDS OF YY PEPTIDE AND USE THEREOF | 2016 |
|
RU2726777C2 |
| ANALOGUES OF EGF(A) WITH SUBSTITUENTS-FATTY ACIDS | 2017 |
|
RU2747877C2 |
| SELECTIVE PYY COMPOUNDS AND USES THEREOF | 2014 |
|
RU2678312C1 |
| DOUBLE ACYLATED GLP-1 DERIVATIVES | 2012 |
|
RU2602601C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
| INSULIN DERIVATIVES CONTAINING ADDITIONAL DISULFIDE BONDS | 2011 |
|
RU2598273C2 |
| GLUCAGON-LIKE PEPTIDE-1 (GLP-1) DERIVATIVES | 2004 |
|
RU2401276C2 |
